HUMULIN R (insulin human) by Eli Lilly and Company. Approved for insulin [epc]. First approved in 1982.
Drug data last refreshed 3h ago · AI intelligence enriched 1mo ago
HUMULIN R is a rapid-acting human insulin approved in 1982 for the treatment of diabetes mellitus. It is a recombinant DNA origin insulin that mimics the body's natural insulin to regulate blood glucose levels. HUMULIN R is administered via subcutaneous injection and is used in both Type 1 and Type 2 diabetes management.
As HUMULIN R approaches loss of exclusivity with mature market dynamics, brand teams are expected to shift focus toward value defense, cost containment, and patient retention strategies rather than growth initiatives.
Insulin
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Comparative Study of Rinsulin R (GEROPHARM) and Humulin Regular (Eli Lilly) Euglycemic Hyperinsulinemic Clamp Method
Comparing Insulin Aspart With Fast-acting Insulin Human in Subjects With Type 1 Diabetes
Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20
Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Type 1 Diabetics
Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Healthy Subjects.
Worked on HUMULIN R at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moHUMULIN R roles focus on defending market position, managing payer relationships, and optimizing pricing as LOE approaches. Career growth is limited by the product's mature lifecycle; positions are geared toward cost-containment, value demonstration, and patient retention rather than innovation-driven activities.